|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Opinions: Gynecological Cancers - Niche Opportunities in Advanced Disease
Datamonitor, Dec 2006, Pages: 184
Cases of endometrial cancer are set to rise in developed countries due to an increase in risk factors such as obesity.
In contrast, while incidence of cervical cancer is set to decrease in developed countries following the implementation of anti-HPV immunization with Merck & Cos Gardasil and GlaxoSmithKlines Cervarix, it will remain a major cause of cancer-related death in the developing world.
Scope of this title:
- Current diagnosis and treatment of endometrial, cervical, vaginal and vulvar cancer, including treatment regimens by stage of disease
- Issues and unmet needs in current treatment, screening and potential anti-HPV vaccination programs
- Examination of pipeline activity and potential future opportunities for drug developers
- Stakeholder opinions and interview transcripts based on qualitative interviews with five opinion leaders from the US and Europe
Highlights of this title:
- The advent of anti-HPV vaccines capable of preventing cervical cancer, Merck & Cos Gardasil and GlaxoSmithKlines Cervarix, represent a major breakthrough, capable of significantly reducing the burden of disease. However, maximal impact will depend on the ease by which cash-strapped developing countries are able to gain access to these vaccines.
- Despite being the most common of the gynecological malignancies, drug development for endometrial cancer is minimal. Given the high rate of early diagnosis and cure, the development of systemic therapies for metastatic disease has not been prioritized. This relatively inactive pipeline may become more of an issue as disease incidence increases.
- While ample Phase I/II clinical trial data has been reported for the gynecological malignancies, only a small number of Phase III studies have been completed to corroborate earlier results. To fully define treatment strategies and provide solid evidence for clinical decision making, more large-scale, randomized clinical trials are necessary.
Reasons to order your copy:
- Identify the limitations of current therapy for gynecological cancer and the potential of future therapy
- Understand current epidemiological trends in gynecological cancer and ongoing treatment controversies
- Assess the opportunities for innovative targeted therapies in gynecological cancer, particularly in metastatic disease
Customers who bought this item also bought
Stakeholder Opinions: Melanoma - Lucrative Commercial Opportunities Persist
Stakeholder Opinions: Parkinsons Disease - Review of Key Commercial Opportunities in the Symptomatic Treatment Market
Stakeholder Opinions: HIV/HCV Co-infection - Whose Niche?
Stakeholder Opinions: Systemic Lupus Erythematosus - On the Verge of a Breakthough
Stakeholder Opinions: HIV/ HBV Co-infection - More Potency, More Policy
Stakeholder Insight: Alzheimers Disease - Prescribing Trends Indicate That Neurologists Are Not Adhering to Guidelines
Stakeholder Opinions: Community Acquired Respiratory Tract Infections - Room for Ketek?
Stakeholder Opinions: Respiratory Syncytial Virus (RSV) - A Market Yet to Reach its Full Potential
|
|
|
|
